Clinical Trial Update: PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating epsilon-aminocaproic acid to prevent bleeding in patients with hematological malignancies and thrombocytopenia; study terminated with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies
• Thrombocytopenia

Drugs mentioned

• Epsilon-aminocaproic acid (epsilon-aminocaproic acid)

Snippet

Sponsor: Emory University | Conditions: Hematological Malignancies, Thrombocytopenia | Phase 2 | Status: TERMINATED | Results posted: 2022-07-19